Optimized administration regimen of lopinavir for a myocardial ischaemia reperfusion study in Sprague–Dawley rats. (April 2013)

• Record Type: Journal Article
• Authors: Katayama, M; Jiamsripong, P; Bukatina, A E; Lombari, T R; Mcmahon, E M; Gades, N M; Belohlavek, M
• Is Part Of: Laboratory animals. Volume 47:Number 2(2013)
• Page Start: 122
• Page End: 126
• Publication Date: 2013-04
• Subjects: Animal model -- lopinavir -- pharmacokinetics; Animal experimentation -- Periodicals; Animal models in research -- Periodicals; Laboratory animals -- Periodicals; Animal welfare -- Periodicals; 636.0885
• DOI: 10.1177/0023677213476864
• Languages: English
• ISSNs: 0023-6772

Abstract

Pharmacokinetics of drugs may differ between small and large mammals (including humans); therefore, drug testing in animal models must be carefully designed. Sprague–Dawley rats were used in cardiac experiments, during which the lopinavir concentration in serum had to match human therapeutic levels (4–10 μg/mL). Lopinavir was administered as a co-formulated drug of lopinavir and ritonavir. It was found that after a single administration of a standard human peroral dose (lopinavir 13.3 mg/kg of body weight), the serum concentration of lopinavir was only one-tenth of the target level. It remained below the minimum target level even after 10-fold the standard dose was administered. After initial pilot tests, a dose escalation study was conducted with oral doses 10- and 15-fold the standard clinical dose of lopinavir (i.e. 133 and 200 mg/kg, respectively). A second administration 2 h later effectively increased and maintained higher concentrations during the experimental ischaemia and reperfusion periods. A dose-dependent increase in serum concentration of the drug was observed. Thus, the target therapeutic serum level of lopinavir in the rats was achieved by administrating 10- to 15-fold the standard human dose twice, separated by a 2 h interval.